150 related articles for article (PubMed ID: 37509411)
1. Early Age of Onset Is an Independent Predictor for a Worse Response to Neoadjuvant Therapies in Sporadic Rectal Cancer Patients.
Foppa C; Maroli A; Luberto A; La Raja C; Spaggiari P; Bonifacio C; De Zanet S; Montorsi M; Piscuoglio S; Terracciano LM; Santoro A; Spinelli A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509411
[TBL] [Abstract][Full Text] [Related]
2. Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients.
Foppa C; Tamburello S; Maroli A; Carvello M; Poliani L; Laghi L; Malesci A; Montorsi M; Perea J; Spinelli A
Eur J Surg Oncol; 2022 Apr; 48(4):857-863. PubMed ID: 34740480
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant radiation above NCCN guidelines for rectal cancer is associated with age under 50 and early clinical stage.
Bliggenstorfer JT; Bingmer K; Ofshteyn A; Stein SL; Charles R; Steinhagen E
Surg Endosc; 2022 May; 36(5):2925-2935. PubMed ID: 34114070
[TBL] [Abstract][Full Text] [Related]
4. Role of Perirectal Fat in the Carcinogenesis and Development of Early-Onset Rectal Cancer.
Pan AF; Zheng NX; Wang J; Kabemba JLT; Zheng K; Shen F; Zhang W; Gao XH
J Oncol; 2022; 2022():4061142. PubMed ID: 35368890
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
6. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
7. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
8. [Survival analysis of early-onset locally advanced rectal cancer: a retrospective study based on the Surveillance, Epidemiology, and End Results (SEER) database].
Xiao TX; Hou WY; Mei SW; Liu Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):75-83. PubMed ID: 36650003
[No Abstract] [Full Text] [Related]
9. Different Oncologic Outcomes in Early-Onset and Late-Onset Sporadic Colorectal Cancer: A Regression Analysis on 2073 Patients.
Foppa C; Maroli A; Lauricella S; Luberto A; La Raja C; Bunino F; Carvello M; Sacchi M; De Lucia F; Clerico G; Montorsi M; Spinelli A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551724
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer.
Hartman TR; Demidova EV; Lesh RW; Hoang L; Richardson M; Forman A; Kessler L; Speare V; Golemis EA; Hall MJ; Daly MB; Arora S
Sci Rep; 2020 Aug; 10(1):13518. PubMed ID: 32782288
[TBL] [Abstract][Full Text] [Related]
11. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
13. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
[TBL] [Abstract][Full Text] [Related]
14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
15. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
16. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
[TBL] [Abstract][Full Text] [Related]
17. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life of patients with locally advanced rectal cancer after neoadjuvant therapy and sphincter-preserving surgery].
Shi WK; Li YH; Qiu XY; Xiao Y; Zhou JL; Wu B; Lin GL
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):348-356. PubMed ID: 35461204
[No Abstract] [Full Text] [Related]
19. A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study).
Gelsomino F; Bertolini F; Luppi G; Spallanzani A; Pettorelli E; Reggiani Bonetti L; Meduri B; Manco G; Conte P; Cascinu S
Clin Colorectal Cancer; 2017 Dec; 16(4):410-415.e1. PubMed ID: 28410832
[TBL] [Abstract][Full Text] [Related]
20. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer.
Shiraishi T; Sasaki T; Ikeda K; Tsukada Y; Nishizawa Y; Ito M
BMC Cancer; 2019 Dec; 19(1):1222. PubMed ID: 31842797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
